Progression of preventive treatment of latent tuberculosis infection in close contacts of patients with tuberculosis

doi:10.3969/j.issn.1000-6621.2019.09.020

Abstract

Abstract:

Close contacts of tuberculosis patients is one of the high-risk groups for Mycobacterium tuberculosis infection and active tuberculosis. Preventive treatment of close contacts with latent infection can decrease the incidence of tuberculosis. This study discusses the current researches on preventive treatment in close contacts with latent tuberculosis infection to clarify the research progress and existing problems of preventive treatment in this group, and to provide suggestions for further researches and explorations in the future.

Key words: Tuberculosis,pulmonary, Contact tracing, Latent tuberculosis, Antibiotic prophylaxis, Review literature as topic, Preventive treatment

Zhe-wen REN,Jun CHENG,Cai-hong XU,Hui ZHANG. Progression of preventive treatment of latent tuberculosis infection in close contacts of patients with tuberculosis[J]. Chinese Journal of Antituberculosis, 2019, 41(9): 1021-1024. doi: 10.3969/j.issn.1000-6621.2019.09.020

Figures/Tables 1

References 30

[1]	Mack U, Migliori GB, Sester M , et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J, 2009,33(5):956-973.
[2]	World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization, 2018.
[3]	Houben RM, Dodd PJ . The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med, 2016,13(10):e1002152.
[4]	Comstock GW, Livesay VT, Woolpert SF . The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol, 1974,99(2):131-138.
[5]	Fox GJ, Barry SE, Britton WJ , et al. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J, 2013,41(1):140-156.
[6]	Greenaway C, Palayew M, Menzies D . Yield of casual contact investigation by the hour. Int J Tuberc Lung Dis, 2003,7(12 Suppl 3):S479-485.
[7]	World Health Organization. Latent TB infection: Updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
[8]	National Tuberculosis Controllers Association, Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep, 2005,54(RR-15):1-47.
[9]	Horwitz O, Payne PG, Wilbek E . Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ, 1966,35(4):509-526.
[10]	Ferebee SH, Mount FW . Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis, 1962,85:490-510.
[11]	Triasih R, Robertson CF, Duke T , et al. A prospective evaluation of the symptom-based screening approach to the management of children who are contacts of tuberculosis cases. Clini Infect Dis, 2015,60(1):12-18.
[12]	Zelner JL, Murray MB, Becerra MC , et al. Bacillus Calmette-Guérin and isoniazid preventive therapy protect contacts of patients with tuberculosis. Am J Respir Crit Care Med, 2014,189(7):853-859.
[13]	World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization, 2015.
[14]	Wysocki AD, Villa TC, Arakawa T , et al. Latent tuberculosis infection diagnostic and treatment cascade among contacts in primary health care in a city of Sao Paulo State, Brazil: Cross-sectional study. PLoS One, 2016,11(6):e0155348.
[15]	Okwara FN, Oyore JP, Were FN , et al. Correlates of isoniazid preventive therapy failure in child household contacts with infectious tuberculosis in high burden settings in Nairobi, Kenya-a cohort study. BMC Infect Dis, 2017,17(1):623.
[16]	Sterling TR, Villarino ME, Borisov AS , et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011,365(23):2155-2166.
[17]	张燕媚, 詹星煌 . 控制肺结核患者家庭中密切接触者感染及预防服药效果观察. 河南预防医学杂志, 2016,27(6):421-423.
[18]	Datiko DG, Yassin MA, Theobald SJ , et al. A community-based isoniazid preventive therapy for the prevention of childhood tuberculosis in Ethiopia. Int J Tuberc Lung Dis, 2017,21(9):1002-1007.
[19]	Sun HY, Huang YW, Huang WC , et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb), 2018,111:121-126.
[20]	翁丽霞, 王勇 . 学校涂阳肺结核密切接触者筛查及预防性服药效果分析. 国际流行病学传染病学杂志, 2014,41(4):258-260.
[21]	戴景涛, 卓玛 . 结核潜伏性感染预防性治疗效果分析. 医药前沿, 2018,8(31):219-220.
[22]	张子胜, 林宪和 . 涂阳肺结核患者家庭密切接触儿童感染发病及预防的研究. 中国热带医学, 2015,15(1):67-69.
[23]	Fiske CT, Yan FX, Hirsch-Moverman Y , et al. Risk factors for treatment default in close contacts with latent tuberculous infection. Int J Tuberc Lung Dis, 2014,18(4):421-427.
[24]	Wang JY, Shu CC, Lee CH , et al. Interferon-gamma release assay and Rifampicin therapy for household contacts of tuberculosis. J Infect, 2012,64(3):291-298.
[25]	Centers for Disease Control and Prevention. Latent tuberculosis infection: A guide for primary health care providers. Atlanta: Centers for Disease Control and Prevention, 2010.
[26]	Bamrah S, Brostrom R, Dorina F , et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009—2012. Int J Tuberc Lung Dis, 2014,18(8):912-918.
[27]	Seddon JA, Hesseling AC, Finlayson H , et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis, 2013,57(12):1676-1684.
[28]	European Centre for Disease Prevention and Control. Management of contacts of MDR TB and XDR TB patients. Stockholm: European Centre for Disease Prevention and Control, 2012.
[29]	American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep, 2000,49(RR-6):1-51.
[30]	National Institute for Health and Care Excellence. Tuberculosis. London: National Institute for Health and Care Excellence, 2016.

治疗方案	剂量	疗程	推荐机构
6~9个月INH单药	成人5mg/kg,儿童10mg/kg,最大剂量300mg/d	6~9个月,每日服药	WHO^[7]
3(Rft+INH)	(1)INH:12岁及以上 15mg/kg;12岁以下,25mg/kg;最大剂量900mg/d。(2)Rft:体质量0.0~14.0kg,300mg/d;体质量14.1~25.0kg,450mg/d;体质量25.1~32.0kg,600mg/d;体质量32.1~50.0kg,750mg/d。最大剂量900mg/d	3个月,1次/周或2次/周	WHO^[7]
4个月RFP单药	成人10mg/kg,儿童15mg/kg,最大剂量600mg/d	4个月,每日服药	WHO^[7]
3(RFP+INH)	(1)INH:成人5mg/kg,儿童10mg/kg,最大剂量300mg/d。(2)RFP:成人10mg/kg,儿童15mg/kg,最大剂量600mg/d	3个月,每日服药	WHO^[7]